The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Hydroxychloroquine Reverses Thrombogenic Properties of Antiphospholipid Antibodies in Mice
Abstract
Background Previous studies have demonstrated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties in vivo. Using such a model in which these antibodies have been shown to increase both the size of an induced thrombus and the duration of time in which such a clot lasts, we investigated whether hydroxychloroquine alters the dynamics of such thrombus formation. Methods and Results Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt). Three control groups of mice were also studied, including mice injected with IgG-APS and then fed with placebo, as well as two other groups injected with IgG from normal human serum and fed either hydroxychloroquine or placebo. A standardized thrombogenic injury was subsequently induced in the femoral vein of each mouse and the area (size) of thrombus measured as well as the total period of time that thrombus was present. Mice treated with hydroxychloroquine and IgG-APS showed significantly smaller thrombi that persisted for a shorter period of time compared with animals treated with IgG-APS and placebo. Conclusions Hydroxychloroquine significantly diminished both thrombus size and total time of thrombus formation in mice previously injected with IgG-APS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental studies have shown that HCQ interferes with the binding of aPL–β2-glycoprotein I complexes to phospholipid surfaces, reverses aPL-induced thrombogenicity, reduces platelet activation, downregulates endothelial tissue factor expression, modulates complement activation and improves endothelial function [3–5].”
From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [5]
In the citing paper
“In addition, HCQ reduces platelet activation, downregulates endothelial tissue factor expression, modulates complement activation and improves endothelial function, collectively targeting multiple thrombo-inflammatory pathways central to APS pathophysiology [3, 5].”
From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [5]
In the citing paper
“Its administration significantly reduced thrombus size and duration [8].”
From Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients (2013) · cites this paper as [8]
Citations
Cites
Handbook of Experimental Immunology.
Denman, A. (1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-6-1376_1 · Cited by 2,414
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
Harris, E. N. (1987) · Lara D. Veeken · doi:10.1093/rheumatology/26.5.324 · Cited by 404
Self-citationBillah, M. M., Lapetina, E. G., & Cuatrecasas, P. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69214-8 · Cited by 369
Derksen, R. H. W. M., de Groot, P. G., Kater, L., & Nieuwenhuis, H. K. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.9.689 · Cited by 240
Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.
Khamashta, M. A., Harris, E. N., Gharavi, A. E., Derue, G., Gil, A., Vázquez, J. J., & Hughes, G. R. V. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.10.849 · Cited by 226
Self-citationPierangeli, S. S., Liu, X. W., Barker, J. H., Anderson, G., & Harris, E. N. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649940 · Cited by 223
Self-citationHarris, E. N. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02530.x · Cited by 222
Self-citationPulmonary Embolism and its Prophylaxis Following the Charnley Total Hip Replacement
JOHNSON, R., Green, J. R., & Charnley, J. (1977) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197709000-00015 · Cited by 179
Campbell, A. L., Pierangeli, S. S., Wellhausen, S. R., & Harris, N. E. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653808 · Cited by 130
Self-citationDoes hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
Wallace, D. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301219 · Cited by 124
Pierangeli, S. S., Liu, X. W., Anderson, G., Barker, J. H., & Harris, E. N. (1996) · Circulation · doi:10.1161/01.cir.94.7.1746 · Cited by 118
Self-citationWallace, D. J., Linker‐Israeli, M., METZGER, A. L., & Stecher, V. J. (1993) · Lupus · doi:10.1177/0961203393002001041 · Cited by 111
Clinical Pharmacokinetics of Slow-Acting Antirheumatic Drugs
Tett, S. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325050-00005 · Cited by 95
Carter, A. E., & Eban, R. E. (1974) · BMJ · doi:10.1136/bmj.3.5923.94 · Cited by 88
On the inhibitory effect of chloroquine on blood platelet aggregation
Jančinová, V., Nosál, R., & Petríková, M. (1994) · Thrombosis Research · doi:10.1016/0049-3848(94)90270-4 · Cited by 84
Olee, T., Pierangeli, S. S., Handley, H. H., Le, D., Wei, X., Lai, C.-J., En, J., Novotny, W. F., Harris, E. N., Woods, V. L., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8606 · Cited by 80
Self-citationOrganization of the Provisional Fibronectin Matrix: Control by Products of Blood Coagulation
Mosher, D. F. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1642734 · Cited by 60
French, J. K., Hurst, N. P., O'Donnell, M. L., & Betts, W. H. (1987) · Annals of the Rheumatic Diseases · doi:10.1136/ard.46.1.42 · Cited by 58
Hydroxychloroquine in Prophylaxis of Pulmonary Embolism Following Hip Arthroplasty
JOHNSON, R., & GHARNLEY, J. (1979) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-197910000-00029 · Cited by 55
Chloroquine inhibits stimulated platelets at the arachidonic acid pathway
Nosál, R., Jančinová, V., & Petríková, M. (1995) · Thrombosis Research · doi:10.1016/0049-3848(95)00028-3 · Cited by 50
USE OF ANTIMALARIAL DRUGS AS "DESLUDGING" AGENTS IN VASCULAR DISEASE PROCESSES
Madow, B. P. (1960) · JAMA · doi:10.1001/jama.1960.03020150054010 · Cited by 49
Stockmans, F., Deckmyn, H., Ja, G., Vermylen, J., & Acland, R. D. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648165 · Cited by 43
McCrea, J. B., Robinson, P. J., & Gerrard, J. M. (1985) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(85)90202-8 · Cited by 38
Steady-State Pharmacokinetics of Hydroxychloroquine in Rheumatoid Arthritis Patients
Miller, D. R., Khalil, S. K. W., & Nygard, G. A. (1991) · DICP · doi:10.1177/106002809102501202 · Cited by 36
Cooke, E., Dawson, M., Ibbotson, R. M., Bowcock, S., Ainsworth, M., & Pilcher, M. F. (1977) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-197759040-00013 · Cited by 28
Ernst, E., Rose, M., & Lee, R. (1984) · PubMed · Cited by 27
[Antiaggregation action of chloroquine].
Bertrand, E., Cloitre, B., Ticolat, R., et al. (1990) · PubMed · Cited by 26
[Antiaggregation action of chloroquine].
Bertrand, E., Cloitre, B., Ticolat, R., Kouad-Bile, R., Gautier, C., Abiyou, G. O., & Bohui, B. Y. (1990) · PubMed · Cited by 25
Some rheological properties of blood during anti-rheumatoid therapy.
Bird, H. A., Harkness, J., & Wright (1981) · PubMed · Cited by 11
Research works printed but not linked: 4
- Knisely M, Bloch E. Microscopic observations of intravascular agglutination of red cells and consequent sludging of blood in human diseases. Anat Rec.. 1942;82:426.
- 10.1161/circ.94.7.1746 · DOI
- Cecchi E, Ferraris D. Desludging action of hydroxychloroquine in rheumatoid arthritis. Acta Med Scand.. 1962;8:214-221.
- Bird H, Harkness J, Wright V. Some rheological properties of blood during antirheumatoid therapy. Pharmatherapeutica.. 1981;3:36-39.
Cited by
Sorted by citations
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Ruiz‐Irastorza, G., Crowther, M. A., Branch, W. D., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 875
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740
The Pathogenesis of the Antiphospholipid Syndrome
Giannakopoulos, B., & Krilis, S. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1112830 · Cited by 687
Hydroxychloroquine: From Malaria to Autoimmunity
Ben‐Zvi, I., Kivity, S., Langevitz, P., & Shoenfeld, Y. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8243-x · Cited by 616
Metadata
- Authors
- Edwards, M. H., Pierangeli, S., Liu, X., Barker, J. H., Anderson, G., & Harris, E. N.
- Affiliations
- University of Louisville (US)
- Venue
- Circulation
- Published
- 1997-12-16
- Volume
- 96
- Issue
- 12
- Pages
- 4380-4384
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2001976130
- Cited by
- 250
- References
- 30
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 10 · 2023: 8 · 2022: 6 · 2021: 6 · 2020: 17 · 2019: 9 · 2018: 7 · 2017: 13 · 2016: 14 · 2015: 10 · 2014: 16 · 2013: 11 · 2012: 10
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hydroxychloroquine, antiphospholipid syndrome, anticardiolipin antibodies, antiphospholipid antibodies, thrombosis, thrombus size, thrombogenicity, IgG, thromboprophylaxis
- MeSH terms
- Animals, Dose-Response Relationship, Drug, Humans, Hydroxychloroquine, Immunoglobulin G, Male, Mice, Inbred Strains, Reference Values, Thrombosis, Antiphospholipid Syndrome, Antibodies, Antiphospholipid, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
